Navigation Links
Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%
Date:7/18/2014

regarding VASCUGEL.

Legal Proceedings 

VYVANSE patent litigation

  • On June 25, 2014 Shire announced that Judge Stanley R. Chesler of the US District Court for the District of New Jersey granted Shire's summary judgment motion in a patent infringement lawsuit, holding that certain claims of the patents protecting VYVANSE were both infringed and valid.

    The ruling prevents the five pharmaceutical manufacturers (the ANDA-defendants) who have filed Abbreviated New Drug Applications ("ANDA"s) from launching generic versions of VYVANSE until the earlier of either a successful appeal to the US Court of Appeals for the Federal Circuit, or the expiration of these patents in 2023. To appeal successfully, the ANDA-defendants must overturn the Court's rulings for each of the 18 patent claims.

    The Court's summary judgment ruling concerning Shire's motion included 18 patent claims from four of the FDA Orange Book-listed patents for VYVANSE, which cover VYVANSE's active ingredient, the lisdexamfetamine dimesylate compound, and a method of using lisdexamfetamine dimesylate for the treatment of ADHD.

OTHER DEVELOPMENTS 

Completion of Lumena acquisition 

  • On June 11, 2014 Shire completed its acquisition of Lumena, a biopharmaceutical company with late stage rare disease pipeline assets. Lumena brings to Shire two new novel, once-daily, orally administered therapeutic compounds: SHP625 (formerly LUM001), in Phase 2 clinical development with four potential orphan indications; and SHP626 (formerly LUM002), ready to enter Phase 2 clinical development later in 2014. SHP625 and SHP626 are both inhibitors of the apical sodium-dependent bile acid transporter ("ASBT"), which is primarily responsible for recycling bile acids from the intestine to the liver. SHP625 works by preventing recycling of bile acids back t
    '/>"/>

SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc.
2. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
3. Shire Extends Tender Offer for ViroPharma
4. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
5. MinuteClinic Opens First Clinic Locations in New Hampshire
6. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
7. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
8. Shire to Present at the Morgan Stanley Global Healthcare Conference
9. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
10. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
11. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... CeNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical ... the respected scientific,journal 'Synapse'* on its Phase II ... as a potential treatment for neuropathic,pain. The independent ... undertaken with CNS 5161. , In the study ...
... in Humans of CTI's,Programmable, Pulsatile, Passive Transdermal ... TRENTON, N.J., May 03, 2007 /PRNewswire/,-- Chrono ... of its first phase human clinical trial ... ChronoDose(TM). CTI intends to publish this,clinical data ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
(Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... 26, 2014 India Network Foundation, a ... the USA, announced today a new version of “ ... choosing the right plan for their visiting parents. The ... of the selection process when choosing an insurance plan ... with only a few clicks. Many elderly Asian Indian ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3
... report , THURSDAY, April 15 (HealthDay News) -- ... by several common bacteria, including the most virulent form of ... often acquired from oysters which can cause severe illness or ... infection have remained flat in recent years. , "Overall, this ...
... says back disorders in the working population are among ... world. Disc degeneration is the main suspected origin of ... surgery. But Videman, a researcher in the University of ... common perception that disc degeneration is caused by physical ...
... associated with lower lung function and greater medication use in ... In a paper published online this week in the ... and his colleagues also reported that vitamin D enhances the ... , "Asthmatic children in our study who had low levels ...
... ... senior consultant specializing in managed care, prevention planning and publicly funded health care services ... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ...
... ... for the amount of $34,000.00. , ... Bedford, MA (PRWEB) April, 15, 2010 -- The law firm of Dussault and Zatir settled out ... was injured while on the job while working as a truck-cleaner. The employee was in ...
... condition leaves many undiagnosed, , THURSDAY, April 15 (HealthDay ... detect cases of chlamydia in young men who see ... They say that many urologists are ignoring guidelines on ... which causes inflammation of the testicle and the epididymis, ...
Cached Medicine News:Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:Low vitamin D levels associated with more asthma symptoms and medication use 2Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
For the quantitative in vitro determination of CK-MB in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
Medicine Products: